Treatment of heart failure with beta-blockers. Mechanisms and results

Basic Research in Cardiology, Supplement

Volumn 95, Issue 1, 2000, Pages

  Bohm M ^a   Maack, C ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

adrenergic receptors; Chronic heart failure; Medical therapy; Neuroendocrine activation; Signal transduction

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CATECHOLAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; MILRINONE; NORADRENALIN; XAMOTEROL;

BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; EXERCISE TOLERANCE; EXPERIMENTAL MODEL; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART RATE; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; MORTALITY; NEUROENDOCRINE SYSTEM; NONHUMAN; PATIENT SELECTION; REVIEW; SIGNAL TRANSDUCTION; SYMPATHETIC FUNCTION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; CARDIAC OUTPUT, LOW; HEMODYNAMIC PROCESSES; HUMANS; NEUROSECRETORY SYSTEMS; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICAL ENDURANCE; VENTRICULAR FUNCTION; VENTRICULAR REMODELING;

EID: 0034537732     PISSN: 01759418     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-blockade treatment
2. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease
3. Effects of Carvedilol, a vasodilator-beta blocker, in patients with congestive heart failure due to ischemic heart disease
4. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure
5. Increases of Gi in human hearts with dilated but not ischemic cardiomyopathy
6. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators
7. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts
8. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy
9. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomised trial
10. A randomized trial of β-blockade in heart failure. The Cardiac Insufficienty Bisoprolol Study (CIBIS)
11. Beta-blocking agents in heart failure - Should they be use and how?
12. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: Influence of pre-randomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate
13. Safety and efficacy of carvedilol in severe chronic heart failure
14. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
15. Carvedilol inhibits clinical progression in patients with mild heart failure
16. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
17. Reduction of stress/catecholamine-induced cardiac necrosis by beta1-selective blockade
18. The effect of digoxin on mortality and morbidity in patients with heart failure
19. On behalf of the Australia-New Zealand Heart Failure Research Collaborative Group: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease
20. Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy
21. Effects of beta-blockade on the relation between heart rate and ventricular diastolic perfusion time during exercise in systemic hypertension
22. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial
23. Effects of β-adrenergic receptor blockade on myocardial function and energetics in congestive heart failure
24. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure
25. Comparative hemodynamic, left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart
26. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo
27. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy
28. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
29. β-blocker use in systolic heart failure and dilated cardiomyopathy
30. Turning off the signal: Desensitization of β-adrenergic receptor function
31. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy
32. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with pheochromocytoma
33. Combined alpha-beta-blockade (doxazosin and meto prolol) compared with beta-blockade alone in chronic congestive heart failure
34. Role of surrogate end points in the evaluation of drugs for heart failure
35. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium
36. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
37. Altered myocardial force-frequency relation in human heart failure
38. Xamoterol in severe heart failure
39. Effect of oral milrinone on mortality in severe chronic heart failure
40. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
41. Double-blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial
42. Prevalence of heart failure in three general practices in north west London
43. β-Adrenergic blockers and survival in heart failure
44. Respiratory control and calcium transport in heart mitochondria from the cardiomyopathic hamster
45. Effects of metoprolol on myocardial β-adrenoceptors and Giα-proteins in patients with congestive heart failure
46. Epidemiology of congestive heart failure
47. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
48. Exercise testing in heart failure: A critical review
49. Adverse effects of beta-blocker withdrawal in patients with congestive cardiomyopathy
50. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy
51. Prolongation of survival in congestive cardiomyopathy by beat-receptor blockade
52. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart
53. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
54. Long-term beta-blockade in dilated cardiomyopathy: Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol
55. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy
56. Role of β-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilative cardiomyopathy
57. Haemodynamic metabolic and lymphocyte beta2-adrenoceptor changes following chronic beta-adrenoceptor antagonism
58. Cardiac adrenergic receptor effects of carvedilol